A New Water-soluble Camptothecin Derivative, DX-8951f, Exhibits Potent Antitumor Activity Against Human Tumors in Vitro and in Vivo

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1995 Aug 1

PMID 7559102

Citations 35

Authors

I Mitsui

E Kumazawa

Y Hirota

M Aonuma

M Sugimori

S Ohsuki

K Uoto

A Ejima

H Terasawa

K Sato

Affiliations

Soon will be listed here.

Abstract

CPT-11, a semisynthetic derivative of camptothecin, exhibited strong antitumor activity against lymphoma, lung cancer, colorectal cancer, gastric cancer, ovarian cancer, and cervical cancer. CPT-11 is a pro-drug that is converted to an active metabolite, SN-38, in vivo by enzymes such as carboxylesterase. We synthesized a water-soluble and non-pro-drug analog of camptothecin, DX-8951f. It showed both high in vitro potency against a series of 32 malignant cell lines and significant topoisomerase I inhibition. The anti-proliferative activity of DX-8951f, as indicated by the mean GI50 value, was about 6 and 28 times greater than that of SN-38 or SK&F 10486-A (Topotecan), respectively. These three derivatives of camptothecin showed similar patterns of differential response among 32 cell lines, that is, their spectra of in vitro cytotoxicity were almost the same. The antitumor activity of three doses of DX-8951f administered i.v. at 4-day intervals against human gastric adenocarcinoma SC-6 xenografts was greater than that of CPT-11 or SK&F 10486-A. Moreover, it overcame P-glycoprotein-mediated multi-drug resistance. These data suggest that DX-8951f has a high antitumor activity and is a potential therapeutic agent.

Citing Articles

Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy.

Chang T, Lin C, Wen S, Wu Y, Wei C, Huang J Sci Rep. 2025; 15(1):8735.

PMID: 40082588 PMC: 11906863. DOI: 10.1038/s41598-025-92697-z.

Repurposing FDA-approved compounds to target JAK2 for colon cancer treatment.

Chandrasekhar B, Gor R, Ramalingam S, Thiagarajan A, Sohn H, Madhavan T Discov Oncol. 2024; 15(1):226.

PMID: 38869738 PMC: 11176146. DOI: 10.1007/s12672-024-01050-9.

Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.

Schoffski P, Wang C, Schoffski M, Wozniak A Oncol Res Treat. 2023; 47(1-2):18-41.

PMID: 38016427 PMC: 10860894. DOI: 10.1159/000535491.

Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.

Balamkundu S, Liu C Biomedicines. 2023; 11(11).

PMID: 38002080 PMC: 10669454. DOI: 10.3390/biomedicines11113080.

A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors.

Fontaine S, Carreras C, Reid R, Ashley G, Santi D Cancer Res Commun. 2023; 3(5):908-916.

PMID: 37377899 PMC: 10208276. DOI: 10.1158/2767-9764.CRC-22-0517.

References

Kawato Y, Sekiguchi M, Akahane K, Tsutomi Y, Hirota Y, Kuga H . Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol. 1993; 45(5):444-8. DOI: 10.1111/j.2042-7158.1993.tb05573.x. View

Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S . CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992; 10(8):1225-9. DOI: 10.1200/JCO.1992.10.8.1225. View

Hsiang Y, HERTZBERG R, Hecht S, Liu L . Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985; 260(27):14873-8. View

Weinstein J, Kohn K, Grever M, Viswanadhan V, Rubinstein L, Monks A . Neural computing in cancer drug development: predicting mechanism of action. Science. 1992; 258(5081):447-51. DOI: 10.1126/science.1411538. View

Rowinsky E, Grochow L, Hendricks C, Ettinger D, Forastiere A, Hurowitz L . Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol. 1992; 10(4):647-56. DOI: 10.1200/JCO.1992.10.4.647. View

Gottlieb J, Guarino A, Call J, OLIVERIO V, Block J . Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep. 1970; 54(6):461-70. View

Goldstein L, Galski H, Fojo A, Willingham M, Lai S, Gazdar A . Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989; 81(2):116-24. DOI: 10.1093/jnci/81.2.116. View

Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K . Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 1990; 50(18):5919-24. View

Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M . Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987; 47(22):5944-7. View

10.

Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y . An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 1990; 8(11):1907-12. DOI: 10.1200/JCO.1990.8.11.1907. View

11.

Hertzberg R, Caranfa M, Hecht S . On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 1989; 28(11):4629-38. DOI: 10.1021/bi00437a018. View

12.

Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D . CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn. 1991; 14(6):341-9. DOI: 10.1248/bpb1978.14.341. View

13.

Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K . Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol. 1991; 28(3):192-8. DOI: 10.1007/BF00685508. View

14.

Ishii K, Hasegawa T, Fujisawa K, Andoh T . Rapid purification and characterization of DNA topoisomerase I from cultured mouse mammary carcinoma FM3A cells. J Biol Chem. 1983; 258(20):12728-32. View

15.

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

16.

Futatsuki K, WAKUI A, NAKAO I, Sakata Y, Kambe M, Shimada Y . [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan To Kagaku Ryoho. 1994; 21(7):1033-8. View

17.

Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K . Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991; 51(16):4187-91. View

18.

Hsiang Y, Liu L . Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48(7):1722-6. View

19.

Kingsbury W, Boehm J, Jakas D, Holden K, Hecht S, Gallagher G . Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991; 34(1):98-107. DOI: 10.1021/jm00105a017. View

20.

Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y . A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992; 10(1):16-20. DOI: 10.1200/JCO.1992.10.1.16. View